What is Optibrand?
Optibrand operates at the intersection of advanced optics and data-driven diagnostics, providing patented technology for the auto-capture of retinal images. Its flagship RetCheck Software serves as a critical tool for disease detection, food safety, and animal identification, catering to a broad spectrum of industries ranging from human healthcare to veterinary services and large-scale agriculture. By prioritizing user-friendly and cost-effective hardware-software integration, the company has established a unique market position that enhances the efficacy of artificial intelligence systems in real-world environments. This versatility allows Optibrand to address complex challenges in traceability and health monitoring, ensuring that high-quality diagnostic data is accessible and actionable for practitioners and producers alike.
How much funding has Optibrand raised?
Optibrand has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in Optibrand
PPP
Public-Private Partnership
What's next for Optibrand?
With the recent infusion of capital, Optibrand is poised to execute a multi-pronged growth strategy centered on market penetration and technological refinement. The company is expected to prioritize the expansion of its veterinary and agricultural footprints, where the demand for automated, reliable identification and health screening tools continues to rise. Furthermore, the integration of more sophisticated AI models into the RetCheck ecosystem will likely serve as a primary catalyst for future revenue growth. By optimizing its supply chain and scaling its operational capacity, Optibrand aims to solidify its status as a leader in diagnostic imaging, ultimately improving health outcomes and operational efficiency for its global client base.
See full Optibrand company page
